|
GB8529014D0
(en)
|
1985-11-25 |
1986-01-02 |
Biogen Nv |
Enhanced secretion of heterologous proteins
|
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5571714A
(en)
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
ZA914750B
(en)
|
1990-06-20 |
1992-03-25 |
Bristol Myers Squibb Co |
Methods of modulating blood pressure using tgf-beta and antagonists thereof
|
|
GB9106678D0
(en)
|
1991-03-28 |
1991-05-15 |
Ferguson Mark W J |
Wound healing
|
|
US6008011A
(en)
|
1991-10-31 |
1999-12-28 |
Whitehead Institute For Biomedical Research |
TGF-β type II receptor cDNAs
|
|
AU671606B2
(en)
|
1991-10-31 |
1996-09-05 |
Whitehead Institute For Biomedical Research |
TGF-beta type receptor cDNAs and uses therefor
|
|
US5543143A
(en)
|
1992-03-06 |
1996-08-06 |
Corixa Corporation |
Method for activating macrophages/monocytes
|
|
AU669256B2
(en)
|
1992-10-29 |
1996-05-30 |
Celtrix Pharmaceuticals, Inc. |
Uses of TGF-beta receptor fragment as a therapeutic agent
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
ATE355369T1
(de)
|
1993-10-14 |
2006-03-15 |
Harvard College |
Verfahren zur induzierung und zur erhaltung neuronalen zellen
|
|
US5470952A
(en)
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5541087A
(en)
|
1994-09-14 |
1996-07-30 |
Fuji Immunopharmaceuticals Corporation |
Expression and export technology of proteins as immunofusins
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
US5866323A
(en)
|
1995-04-07 |
1999-02-02 |
Case Western Reserve University |
Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
|
|
NZ306767A
(en)
|
1995-04-11 |
2000-03-27 |
Univ Johns Hopkins |
Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
|
|
US6423501B2
(en)
|
1996-12-13 |
2002-07-23 |
Beth Israel Deaconess Medical Center |
Calcium-independent negative regulation by CD81 of receptor signaling
|
|
DK0975771T3
(da)
|
1997-04-18 |
2007-10-22 |
Biogen Idec Inc |
Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US6294350B1
(en)
|
1997-06-05 |
2001-09-25 |
Dalhousie University |
Methods for treating fibroproliferative diseases
|
|
ZA988461B
(en)
|
1997-09-18 |
1999-03-30 |
Idec Pharma Corp |
Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
|
|
ES2532910T3
(es)
|
1998-04-02 |
2015-04-01 |
Genentech, Inc. |
Variantes de anticuerpos y fragmentos de los mismos
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
AU4572899A
(en)
|
1998-06-16 |
2000-01-05 |
Biogen, Inc. |
Variant type ii tgf-beta receptor fusion proteins and methods
|
|
ES2146552B1
(es)
|
1998-11-24 |
2001-04-16 |
Inst Cientifico Tecnol Navarra |
Peptidos inhibidores de tgf/31
|
|
WO2001066140A1
(en)
|
2000-03-09 |
2001-09-13 |
Genzyme Corporation |
Use of tgf-beta antagonists to treat or to prevent loss of renal function
|
|
WO2001073128A1
(en)
|
2000-03-24 |
2001-10-04 |
Dzgenes, Llc |
DIAGNOSTIC POLYMORPHISMS OF TGF-β-RII PROMOTER
|
|
US20030028905A1
(en)
|
2001-07-31 |
2003-02-06 |
Petra Knaus |
Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
|
|
US20030180301A1
(en)
|
2002-01-22 |
2003-09-25 |
Shaf Keshavjee |
Use of TGF-beta antagonists to treat or to prevent chronic transplant rejection
|
|
US7919084B2
(en)
|
2002-06-17 |
2011-04-05 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
|
CA2513086A1
(en)
|
2002-12-19 |
2004-07-08 |
Scios Inc. |
Treatment of obesity and associated conditions with tgf-.beta. inhibitors
|
|
WO2004098637A1
(en)
|
2003-04-30 |
2004-11-18 |
Genzyme Corporation |
Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US20060229266A1
(en)
|
2003-08-13 |
2006-10-12 |
Kumar Nalin M |
Silencing of tgf-beta receptor type II expression by sirna
|
|
US20050148555A1
(en)
|
2003-08-22 |
2005-07-07 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating COPD and pulmonary hypertension
|
|
WO2005113585A2
(en)
|
2004-05-20 |
2005-12-01 |
Acceleron Pharma Inc. |
Modified tgf-beta superfamily polypeptides
|
|
US7786261B2
(en)
|
2004-09-02 |
2010-08-31 |
National Research Council Of Canada |
Coiled-coil fusion proteins comprising cell receptor domains
|
|
WO2006036729A2
(en)
|
2004-09-22 |
2006-04-06 |
Genzyme Corporation |
USE OF TGF-β ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
|
|
US7795389B2
(en)
|
2004-09-28 |
2010-09-14 |
The Board Of Regents Of The University Of Texas System |
Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
|
|
EP1809324A4
(en)
|
2004-10-13 |
2009-02-25 |
Univ Ohio State Res Found |
METHODS OF TREATING OR PREVENTING LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH VIRUSES
|
|
ES2905923T3
(es)
|
2005-02-08 |
2022-04-12 |
Genzyme Corp |
Anticuerpos de TGFbeta
|
|
JP5342834B2
(ja)
|
2008-09-05 |
2013-11-13 |
日東電工株式会社 |
骨髄線維症処置剤
|
|
ITMI20060181A1
(it)
|
2006-02-03 |
2007-08-04 |
Univ Padova |
Modulatori del tgf-b e loro uso
|
|
EP1998810A4
(en)
|
2006-03-13 |
2009-09-02 |
Univ Johns Hopkins |
INCREASE OF ENDOTHELIAL THROMBORESISTENTEN
|
|
EP2029625A2
(en)
|
2006-06-05 |
2009-03-04 |
Novartis AG |
Use of tgf-beta antagonists in treatment of parathyroid-related disorders
|
|
EP2083863B1
(en)
|
2006-10-03 |
2015-03-18 |
Genzyme Corporation |
Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
|
|
WO2008113185A1
(en)
|
2007-03-19 |
2008-09-25 |
National Research Counsil Of Canada |
Antagonists of ligands and uses thereof
|
|
EP2171062A1
(en)
|
2007-06-15 |
2010-04-07 |
Genzyme Corporation |
Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
|
|
EA017392B1
(ru)
|
2007-08-22 |
2012-12-28 |
Айрм Ллк |
Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ
|
|
EP2238241B1
(en)
|
2008-01-18 |
2013-09-11 |
The Brigham and Women's Hospital, Inc. |
Selective differentiation, identification, and modulation of human th17 cells
|
|
WO2009143309A2
(en)
|
2008-05-21 |
2009-11-26 |
Trustees Of Dartmouth College |
Female reproductive tract and anal prophylaxes
|
|
WO2009152610A1
(en)
|
2008-06-20 |
2009-12-23 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
|
|
KR20110044992A
(ko)
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
ＴＧＦ-β 길항제 다중-표적 결합 단백질
|
|
CA2737271C
(en)
|
2008-09-17 |
2020-06-23 |
National Research Council Of Canada |
Hetero-multivalent binding agents for members of the tgf.beta. superfamily
|
|
WO2010048273A2
(en)
|
2008-10-21 |
2010-04-29 |
President And Fellows Of Harvard College |
Methods and compounds for treatment of neurodegenerative disorders
|
|
AU2010204985A1
(en)
|
2009-01-13 |
2011-08-04 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
WO2010129515A1
(en)
|
2009-05-08 |
2010-11-11 |
The United Satates Of America As Represented By The Secretary, Department Of Health & Human Services |
Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma
|
|
WO2011088148A1
(en)
|
2010-01-12 |
2011-07-21 |
Isis Pharmaceuticals, Inc. |
Modulation of transforming growth factor-beta 1 expression
|
|
PT2542590T
(pt)
*
|
2010-03-05 |
2017-08-31 |
Univ Johns Hopkins |
Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
|
|
CN101852804B
(zh)
|
2010-03-29 |
2013-06-12 |
中国医学科学院病原生物学研究所 |
Gdf15蛋白的抗体的新用途
|
|
US8080568B1
(en)
|
2010-06-29 |
2011-12-20 |
Ewha University - Industry Collaboration Foundation |
2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
|
|
ES2715177T3
(es)
|
2010-09-01 |
2019-06-03 |
Genzyme Corp |
Tratamiento de infarto de miocardio usando antagonistas de tgf-beta
|
|
US20130287688A1
(en)
|
2010-11-18 |
2013-10-31 |
Xtuit Pharmaceuticals, Inc. |
Novel compositions and uses of anti-hypertension agents for cancer therapy
|
|
US8800906B2
(en)
|
2010-12-27 |
2014-08-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
|
|
SG191762A1
(en)
|
2011-01-06 |
2013-08-30 |
Glaxo Group Ltd |
Ligands that bind tgf-beta receptor ii
|
|
JP5588086B2
(ja)
*
|
2011-04-19 |
2014-09-10 |
メリマック ファーマシューティカルズ インコーポレーティッド |
単一特異性および二重特異性抗ＩＧＦ‐１Ｒ抗体および抗ＥｒｂＢ３抗体
|
|
CN108178789B
(zh)
|
2011-04-20 |
2021-11-02 |
阿塞勒隆制药公司 |
内皮糖蛋白多肽及其用途
|
|
CN102850458B
(zh)
|
2011-06-28 |
2014-10-01 |
华博生物医药技术（上海）有限公司 |
新型重组双功能融合蛋白及其制法和用途
|
|
WO2013012648A1
(en)
|
2011-07-15 |
2013-01-24 |
Emory University |
Gdf15 in diagnostic and therapeutic applications
|
|
US9468666B2
(en)
|
2011-08-01 |
2016-10-18 |
Tufts Medical Center, Inc. |
Treatment of heart failure and related conditions
|
|
WO2013059879A1
(en)
|
2011-10-26 |
2013-05-02 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Compositions and methods for the treatment of fibrosis and fibrotic diseases
|
|
PL3489254T3
(pl)
|
2012-04-30 |
2023-01-30 |
Biocon Limited |
Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
|
|
JP2015523966A
(ja)
|
2012-05-16 |
2015-08-20 |
アーディジェン， エルエルシー |
線維症および炎症状態を処置するための多標的調整
|
|
ES2713505T3
(es)
|
2013-03-11 |
2019-05-22 |
Genzyme Corp |
Anticuerpos anti-TGF-beta modificados genéticamente y fragmentos de unión a antígeno
|
|
RU2662991C2
(ru)
*
|
2013-03-12 |
2018-07-31 |
Биокон Лтд. |
Слитые иммуномодулирующие белки и способы их получения
|
|
JP6578271B2
(ja)
|
2013-04-17 |
2019-09-18 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
免疫抑制ＴＧＦ−βシグナルコンバーター
|
|
CN105658672A
(zh)
*
|
2013-08-22 |
2016-06-08 |
阿塞勒隆制药公司 |
TGF-β受体II型变体及其用途
|
|
EP3071215B1
(en)
|
2013-11-21 |
2020-01-08 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
BR112016014952A2
(pt)
|
2014-02-10 |
2017-09-19 |
Merck Patent Gmbh |
Inibição direcionada de tgfbeta
|
|
KR20170005854A
(ko)
|
2014-05-18 |
2017-01-16 |
칠드런'즈 메디컬 센터 코포레이션 |
엑소솜과 관련된 방법 및 조성물
|
|
CN106413740A
(zh)
|
2014-06-13 |
2017-02-15 |
诺华股份有限公司 |
用于降低gdf‑15的serelaxin应用
|
|
CA2956256A1
(en)
|
2014-08-01 |
2016-02-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions relating to treatment of pulmonary arterial hypertension
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
EP3889171A1
(en)
|
2015-04-06 |
2021-10-06 |
Acceleron Pharma Inc. |
Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
|
|
AU2016246602B2
(en)
|
2015-04-06 |
2020-11-19 |
Acceleron Pharma Inc. |
Single-arm type I and type II receptor fusion proteins and uses thereof
|
|
AU2016301380B2
(en)
|
2015-08-04 |
2021-07-01 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
|
EP3344660A4
(en)
|
2015-08-31 |
2019-07-03 |
National Research Council of Canada |
TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF
|
|
WO2017134592A1
(en)
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
MX2019001503A
(es)
|
2016-08-12 |
2019-06-03 |
Merck Patent Gmbh |
Tratamiento conjunto contra el cancer.
|
|
CN110546168B
(zh)
|
2016-09-27 |
2024-03-15 |
埃皮辛特瑞柯斯公司 |
免疫调节性融合蛋白
|
|
BR112019013924A2
(pt)
|
2017-01-07 |
2020-02-11 |
Merck Patent Gmbh |
Regimes de dosagem e formas de dosagem para inibição de tgf-beta direcionada
|
|
IL305536A
(en)
|
2017-03-02 |
2023-10-01 |
Nat Res Council Canada |
TGF–B receptor ectodomain fusion compounds and their uses
|
|
JP2021512919A
(ja)
|
2018-02-09 |
2021-05-20 |
アクセルロン ファーマ インコーポレイテッド |
異所性骨化を処置するための方法
|